Virbac has launched Marfloquin, a marbofloxacin-based antibiotic indicated for the treatment of multiple infectious diseases in cats and dogs. Virbac has launched Marfloquin, a marbofloxacin-based antibiotic indicated for the treatment of multiple infectious diseases in cats and dogs. 

Marfloquin is presented as a palatable, divisible tablet for once daily administration and is available in three tablet strengths:

  • 5 mg for cats and small dogs
  • 20 mg for medium sized dogs
  • 80 mg for large dogs

Virbac Companion Animal Marketing Manager Simon Boulton MRCVS said:  "Marbofloxacin is valued by practices for its efficacy in treating a wide range of skin, soft tissue, urinary tract and respiratory tract infections. The launch of Marfloquin gives them a cost-effective alternative and strengthens our existing antibiotic range, which includes Rilexine (cefalexin) and Enrox (enrofloxacin)."

For more information, contact your territory manager or call Virbac on 01359 243243

 

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.